Lamisil

Terbinafine, the active ingredient in Lamisil, is an allylamine antifungal presented as a tablet for oral use. It treats fungal infections of the skin, nails and related structures in patients as prescribed.

GNH USA supplies Lamisil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamisil (terbinafine) is used to treat fungal infections affecting the skin, hair and nails.

- Tinea pedis: alleviates athlete's foot symptoms and eradicates the causative dermatophyte. - Tinea corporis: clears ringworm lesions on the body by eliminating the fungal infection. - Onychomycosis: improves nail appearance and clears fungal infection of the toenails or fingernails.

Terbinafine may cause a range of adverse reactions, ranging from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal pain or dyspepsia. - Skin reactions: rash, pruritus or mild erythema. - Taste disturbance: altered taste sensation or loss of taste. - Headache: mild to moderate headache episodes.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hematologic effects: neutropenia or eosinophilia.

Before initiating terbinafine therapy, consider the following safety measures.

- Liver function: assess baseline hepatic enzymes and monitor during treatment. - Drug metabolism: avoid use with strong CYP2D6 inhibitors that may increase terbinafine levels. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Age considerations: use caution in elderly patients due to possible hepatic impairment. - Storage: Store at room temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Terbinafine can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase terbinafine exposure. - Cimetidine: can raise terbinafine plasma concentrations. - Itraconazole or ketoconazole: combined use may enhance hepatotoxic risk.

Moderate Interactions (Monitor Closely): - Warfarin: terbinafine may potentiate anticoagulant effect, requiring INR monitoring. - Oral contraceptives: efficacy may be reduced, consider additional contraceptive methods. - Rifampin: may lower terbinafine levels, reducing antifungal efficacy.